Edge Therapeutics, Inc. Form 144 August 28, 2017

UNITED STATES					OMB APPROVAL			
SECURITIES AND EXCHANGE COMMISSION					OMB Number:	3235-0101		
Washington, D.C. 20549					•	June 30, 2020		
					Estimated ave	erage burden		
FORM 144					hours per 1.00 response			
NOTICE OF PROPOSED SALE OF S	SECURITIES				SEC USE ONLY			
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933					DOCUMENT SEQUENCE NO.			
ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker.						CUSIP NUMBER		
1 (a) NAME OF ISSUER (Please type	(b) IRS IDE NO.	NT. (c) S.E NO	.C. FILE	WORK LOCATION				
Edge Therapeutics, Inc.		26-4231384	333-20	6416				
1 (d) ADDRESS OF STREET ISSUER		CITY	STATE	E ZIP CODE	(e) TELEPHONE NO.			
300 Connell Drive Suite 4000		Berkeley Heights	NJ	07922	AREA CODE	NUMBER		
					800	208-3343		
2 (a) NAME OF (b) RELATICE ISSUER WHOSE ACCOUNT THE SECURITIES ARE TO BE SOLD	ONSHIP TO	(c) ADDRE	SS STREET	CITY	STATE	ZIP CODE		
Albert N Marchio II Officer		PO Box 601 St.	, 211 Main	Gladstone	NJ	07934-0601		
INSTRUCTION: The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the S.E.C. File Number.								
3 (a) (b)	SEC USE ONLY	(c)	(d)	(e)	(f)	(g)		
Title of Name and Address of the Each Broker Through Class of Whom the Securities are	Broker-Deal File Number	ler Number of Shares	Aggregate Market Value	Number of Shares	Approximat Date of Sale			

# Edgar Filing: Edge Therapeutics, Inc. - Form 144

Securities To Be Sold	to be Offered or Each Market Maker who is Acquiring the Securities	or Other Units To Be Sold (See instr. 3(c))	(See instr. 3(d))	or Other Units Outstanding (See instr. 3(e))	(See instr. 3(f)) (MO. DAY YR.)	Exchange (See instr. 3(g))
Common stock	Credit Suisse Securities (USA) LLC Eleven Madison Avenue, 9th Floor New York, NY 10010-3629	1,000	\$10,393	5,861	08/23/2017	Nasdaq
Common stock	Computershare 480 Washington Blvd., 26th Floor Jersey City, NJ 07310	2,500	\$26,260	3,361	08/29/2017	Nasdaq

### **INSTRUCTIONS:**

- 1.(a) Name of issuer
  - (b) Issuer's I.R.S. Identification Number
  - (c) Issuer's S.E.C. file number, if any
  - (d) Issuer's address, including zip code
  - (e) Issuer's telephone number, including area code
- 2.(a) Name of person for whose account the securities are to be sold
  - Such person's relationship to the issuer (e.g.,
  - (b) officer, director, 10% stockholder, or member of immediate family of any of the foregoing)
  - (c) Such person's address, including zip code

3.(a) Title of the class of securities to be sold

- Name and address of each broker through whom the securities are intended to be sold
- Number of shares or other units to be sold (if debt securities, give the aggregate face amount)
- (d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to filing of this notice Number of shares or other units of the class outstanding, or
- (e) if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer
- (f) Approximate date on which the securities are to be sold Name of each securities exchange, if any, on which the securities are intended to be sold

Potential persons who are to respond to the collection of information contained in this form are **SEC 1147** not required to respond unless the form displays a currently valid OMB control number. (08-07)

## TABLE I — SECURITIES TO BE SOLD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired (If gift, also give date donor acquired)	Amount of Securities Acquired	Date of Payment	Nature of Payment
Common		Acquired 1,000 shares at IPO	Edge Therapeutics,			
Stock	10/6/2015	Acquired 5,681 shares of preferred	Inc.	1,000	10/1/15	Wire
Preferred stock	11/3/2014	nverted into common shares on a e to one basis	Edge Therapeutics, Inc.	5,681	10/6/2014	Check

INSTRUCTIONS: If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

#### TABLE II — SECURITIES SOLD DURING THE PAST 3 MONTHS

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

Name and Address of Seller Title of Securities Sold Date of Sale Securities Sold Gross Proceeds

None None

## **REMARKS:**

#### **INSTRUCTIONS:**

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

#### ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

8/28/2017 /s/ Albert N Marchio II

REMARKS: 4

DATE OF NOTICE (SIGNATURE)

DATE OF PLAN ADOPTION OR GIVING OF INSTRUCTION, IF RELYING ON RULE 10B5-1

The notice shall be signed by the person for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

SEC 1147 (02-08)